LEIDEN JEFFREY M 4

What Happened

• Jeffrey M. Leiden, Executive Chairman and Director of Vertex Pharmaceuticals (VRTX), was granted 8,269 restricted stock units (RSUs) that fully vested on Feb 17, 2026 (acquired at $0.00). To satisfy tax withholding obligations, 2,964 of those shares were surrendered/ disposed on Feb 18, 2026 at $483.75 per share, totaling $1,433,835. The award (code A) and the withholding/disposition (code F) are routine actions tied to vesting.

Key Details

• Dates and prices:
  • Feb 17, 2026: RSU award of 8,269 shares (acquisition at $0.00).
  • Feb 18, 2026: 2,964 shares disposed at $483.75 per share for tax/payment = $1,433,835.
• Footnote: F1 states the RSU award fully vested upon grant.
• Filing: Form 4 filed Feb 19, 2026 (covers transactions on Feb 17–18); filing appears within the normal two-business-day window.
• Shares owned after transaction: not specified in the provided summary of the filing.

Context

• This was primarily an RSU vesting with shares withheld/sold to cover taxes — a common, administrative transaction that does not necessarily indicate a change in insider sentiment. The award increased Leiden’s holdings via vested RSUs (acquired at $0), while the disposition reflects tax withholding rather than an open-market investment decision.